Methotrexate, a DHFR-inhibiting drug approved in the US since 1953, is known for treating various conditions such as acute lymphoblastic leukemia, breast cancer, severe psoriasis, and rheumatoid arthritis in both adults and children.

Curadev proudly launches CRD3874, an innovative allosteric small molecule that uniquely activates the STING pathway without targeting the cGAMP site.

Pregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions.

Repare Therapeutics Inc. announced the first patient has been treated in their LIONS Phase 1 trial, focusing on RP-1664 – a leading oral inhibitor targeting polo-like kinase 4, intended for solo therapy.

Topiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services.

Nuvig Therapeutics, Inc., initiates first human trial of NVG-2089 for treating inflammatory myopathies and severe autoimmune skin diseases.

Allopurinol, sold as Zyloprim®, is a drug that reduces uric acid in gout, kidney stones, and some cancers.

Atara Biotherapeutics Reports Filing a New Drug Application for ATA3219 Aimed at Treating Lupus Kidney Inflammation.

Aripiprazole, sold as Abilify Discmelt®, is an atypical antipsychotic for treating schizophrenia, bipolar disorder, depression, autism-related irritability, and Tourette's syndrome.

CalciMedica has received approval from the FDA to proceed with a Phase 2 study of Auxora™ in treating severe cases of acute kidney injury.

Guaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products.

Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.